Better Science Doesn’t Sell Itself
Stay Informed
Get insights delivered to your inbox
Subscribe to receive the latest research, perspectives, and strategic insights from Shapiro+Raj.
Key Takeaways
-
Adoption is a behavior, not a fact — physicians don't change what they prescribe simply because the evidence crosses a threshold. Superior data alone rarely moves practice.
-
Commissioning more awareness or tracking studies documents the adoption gap in finer detail. It doesn't explain what's holding the behavior in place, so it doesn't close the gap.
-
The real barrier is often structural, not attitudinal: who identifies the patient, which specialist controls the decision, what diagnostic proof is required, and whether the new approach fits the existing clinical pathway.
-
Useful Drivers & Barriers research has to explain why each barrier exists, who can move it, and where the commercial, medical, access, or educational leverage points sit — not just list objections.
-
Behavioral insight has to arrive while the launch curve is still bendable. Once prescribing habits harden, the same insight becomes an explanation for what was missed, not a lever to change it.
In short: Strong clinical data is necessary for adoption but not sufficient. What actually moves physician behavior is understanding — and designing around — the friction, habit, risk, and structural barriers standing between the evidence and the prescription pad.
I’m a behavioral scientist, which means I’ve spent my life studying the gap between what people know and what they do. I don’t have to study it very hard. I only have to look at myself.
I have known, with the full authority of evidence, that I should do a dozen things I don’t, and stop doing several I keep doing. My wife has presented the data. My doctor has presented the data. The facts have never been the problem. The facts have never once, on their own, changed my behavior.
If they don’t change mine, why do we keep expecting them to change a physician’s?
Why Does Superior Clinical Data Fail to Change Prescribing Behavior?
The science is genuinely better. A cleaner mechanism, a stronger safety profile, a formulation that solves a real problem. The data is unimpeachable. The publications land. And adoption is slower than the forecast promised. Everyone is confused, because on the merits, this should be selling itself.
Nothing sells itself. Adoption is not a fact that becomes true once the evidence crosses a threshold. Adoption is a behavior. And behaviors don’t move on evidence — they move on friction, habit, belief, risk, identity, the weight of the last conversation, the fear of being first to switch or last to.
The pattern shows up in the research, too. A large systematic review of guideline-based behavior-change interventions across healthcare found that guidelines influenced clinician behavior positively in less than half of the studies reviewed — and prescribing was the single most-studied behavior in that body of research.¹ Evidence, on its own, is a coin flip at best.
Why Doesn’t More Data Close the Adoption Gap?
So the team commissions more data. Another awareness study. Another tracker confirming that yes, physicians are aware; yes, they rate the profile highly; and no, they haven’t changed what they prescribe on Monday. The data documents the gap in ever-finer resolution. It does not close it — because the question was never “is there a gap.” It’s “what, specifically, is holding this behavior in place, and what would release it?”
What Actually Holds Physician Adoption in Place?
Sometimes what holds adoption in place is larger than any one physician. The barrier may be built into the treatment pathway: who identifies the patient, which specialist controls the decision, what diagnostic proof is required, where multidisciplinary teams reach agreement, and whether the new approach has a legitimate place in the existing clinical frame.
That means useful Drivers & Barriers research must do more than list objections. It must explain why each barrier exists, who can move it, and where the commercial, medical, access, or educational leverage points actually sit.
That’s the Insight factor. Data measures the what. Only behavioral insight explains the why — and the why is the only thing you can act on.
How Does the Insight Equation Apply to Physician Adoption?
A better mechanism multiplied by near-zero understanding of the behavior around it collapses to a beautiful drug nobody switches to. The best mechanism doesn’t win. The most adoptable one does. And adoptability isn’t something you discover in the molecule — it’s something you design into the behavior, once you understand the behavior.
And you have to understand it while the launch curve is still bendable. Behavioral insight that arrives after prescribing habits have hardened is a very expensive explanation of why you missed.
What Should Commercial and Medical Teams Do When Adoption Lags?
Resist the reflex.
When adoption lags, don’t reach for more proof. You have proof. What you’re missing is an understanding of the human being who has the proof and still won’t move.
That’s the work my team at Shapiro+Raj does as a life sciences insights consultancy — behavioral science that gets under what people say to why they do it, and turns that into what you change. Because better science is necessary. It has never once been sufficient.
The facts have never changed my behavior. They won’t change your customer’s either. Something else does. We find it.
See how Shapiro+Raj mapped the structural, behavioral, and specialist dynamics shaping adoption for a new treatment approach across four healthcare systems
¹ Systematic review, “Please mind the gap between guidelines & behavior change,” ScienceDirect, PubMed.
Frequently asked questions
Why don't physicians change prescribing behavior when the clinical evidence is strong?
Prescribing is a behavior, not a conclusion drawn from data. Systematic research on guideline-based interventions shows that evidence and guidelines change clinician behavior positively in less than half of studied cases — friction, habit, risk, and workflow structure typically matter as much as the data itself.¹
What is Drivers & Barriers research in pharma commercial strategy?
Drivers & Barriers research identifies the specific structural, behavioral, and belief-based factors keeping a physician, specialist, or care team from adopting a new treatment approach — and, done well, explains why each barrier exists and who has the leverage to move it, rather than simply cataloguing objections.
How is behavioral insight different from a physician awareness study?
An awareness or tracking study measures whether physicians know about and rate a treatment favorably. It documents the adoption gap but doesn’t explain what’s causing it. Behavioral insight goes further, identifying the specific friction points — clinical pathway structure, specialist gatekeeping, diagnostic requirements, risk perception — that are actually holding adoption in place.
Why does timing matter for behavioral insight in a launch?
Prescribing habits harden over time. Behavioral insight delivered while the launch curve is still bendable can inform real changes to messaging, access support, or educational strategy. The same insight delivered after habits have set becomes a retrospective explanation rather than something a team can act on.
How does Shapiro+Raj approach physician adoption differently than traditional market research?
As a life sciences insights consultancy, Shapiro+Raj combines behavioral science with commercial insights work to explain the why behind physician decisions — not just report the what. That distinction shapes how Drivers & Barriers studies are scoped, from identifying structural pathway barriers to pinpointing who within a care team actually controls the decision.
Can better clinical data alone drive faster adoption?
Rarely on its own. Strong data is necessary groundwork, but the research consistently shows that guidelines and evidence alone produce inconsistent behavior change.¹ Adoption tends to move faster when commercial and medical teams also address the structural and behavioral barriers sitting between the evidence and the prescription.